CPAP statistics span treatment use, symptom outcomes, apnea reduction, cardiovascular measures, support interventions and device-industry revenue. The figures below identify the population, geography, measurement period and adherence definition for each result.
Key CPAP Statistics
The most useful headline figures include:
- 41.4% of 295 adults with moderate or severe obstructive sleep apnea met the adherence threshold of at least 4 hours per night on at least 5 days per week at a median 74.8-month follow-up.
- 51.8% of patients with severe obstructive sleep apnea were adherent versus 22.1% with moderate disease in the same long-term cohort.
- Mean CPAP use was 4.5 ± 1 hours per night across 136 randomized trials published from 1984 through 2024, covering 8,827 adults with obstructive sleep apnea.
- CPAP reduced Epworth Sleepiness Scale scores by 2.14 points in a meta-analysis of 41 randomized trials involving 7,332 people with obstructive sleep apnea.
- CPAP reduced the apnea-hypopnea index by 25.4 events per hour versus conservative management in a 77-randomized-trial review through August 2013.
- CPAP produced an apnea-hypopnea index 7.08 events per hour lower than mandibular advancement devices in a 14-trial review through October 2019.
- APAP and fixed CPAP differed by -0.20 apnea-hypopnea events per hour in a nine-trial meta-analysis of 282 adults with obstructive sleep apnea.
- CPAP lowered 24-hour mean arterial pressure by 2.4 mmHg versus control after 12 weeks in a randomized trial of adults with cardiovascular disease or multiple risk factors and obstructive sleep apnea.
- Mean CPAP adherence was 3.1 hours per day over a mean 3.25-year follow-up in a 4,186-person cardiovascular-outcome meta-analysis.
- The intention-to-treat hazard ratio for a first major adverse cardiac or cerebrovascular event was 1.01 for CPAP versus usual care in that cardiovascular population.
- Phone coaching raised four-month use above 3 hours per night from 65% to 75% in a randomized trial of newly diagnosed patients in France.
- Motivational interviewing produced 4.63 hours of CPAP use per night versus 3.16 hours at three months among 100 Australian adults with newly diagnosed obstructive sleep apnea.
- Daytime acclimation produced 5.7 ± 1.0 hours of use per night versus 3.9 ± 1.1 with usual care at one month in 246 adults with moderate or severe obstructive sleep apnea.
- ResMed device revenue reached $2,665.2 million in fiscal 2025, up from $2,444.0 million in fiscal 2024.
- Devices represented approximately 52% of ResMed net revenue in fiscal 2025, although that segment includes CPAP/APAP, bilevel, ASV and HFT devices.
Contents
- CPAP adherence statistics and long-term use
- CPAP trial data and sleepiness outcomes
- Apnea reduction and CPAP alternatives
- Blood pressure and cardiovascular CPAP outcomes
- CPAP acceptance and adherence interventions
- CPAP device-market and connected-care figures
CPAP Adherence Statistics and Long-Term Use
Adherence is not one universal measure. Studies in this set use at least 4 hours nightly, more than 3 hours nightly, or a combined hours-and-days threshold, so percentages should not be treated as interchangeable.
In a 295-adult cohort with moderate or severe obstructive sleep apnea syndrome, 41.4% met at least 4 hours per night on at least 5 days per week after a median 74.8 months. The long-term cohort reported 42.3% adherence among males and 37.0% among females; lower disease severity had a 0.66 hazard ratio for non-adherence, while smoking and previous cardiovascular events had hazard ratios of 1.72 and 1.95. Long-term prediction of adherence to continuous positive air pressure therapy reports observational subgroup and multivariable associations, not causal effects.
Severity was strongly associated with observed use in that cohort: 51.8% of people with severe disease were adherent compared with 22.1% with moderate disease. These are single-cohort estimates under the study’s stated definition.
The SAVE adherence analysis shows why early use can overstate durable use. Among 275 adults with cardiovascular disease and obstructive sleep apnea, mean use fell from 4.4 hours nightly at one month to 3.8 at six months and 3.3 at 12 months; during screening, 603 of 710 patients, or 85%, used sham CPAP for at least 3 hours nightly during the one-week run-in. Predictors of Long-Term Adherence in the SAVE Study labels the run-in result separately from long-term adherence.
A 2025 meta-analysis of randomized trials published from 1984 through 2024 included 8,827 adults and found mean nocturnal use of 4.5 ± 1 hours. The share of the 136 trials reporting at least 4, 5 or 6 hours nightly was 71.3%, 34.1% and 7.8%, respectively; these are trial-level reporting thresholds, not patient percentages. Adherence to CPAP in Randomized Controlled Trials describes the pooled population as mean age 55 years, BMI 31 kg/m², ESS 10.0 and AHI 35.7 events per hour.
CPAP Trial Data and Sleepiness Outcomes
Randomized evidence measures both use and daytime symptoms. ESS means Epworth Sleepiness Scale, while AHI means apnea-hypopnea index; neither is itself a CPAP adherence measure.
A meta-analysis of 41 randomized trials published from January 1994 through October 2021 included 7,332 people with obstructive sleep apnea. It found a 2.14-point reduction in ESS, a 1.23-point improvement in multiple sleep latency test results and a 1.6-point improvement in maintenance of wakefulness test results. Predictors of the Efficacy for Daytime Sleepiness found that in mild disease, sleepiness benefit was concentrated among patients younger than 50, with BMI at least 30, ESS at least 11, adherence at least 3 hours nightly and treatment lasting at least two months.
A randomized study of 1,105 adults found active CPAP use averaged 4.87 hours nightly versus 4.07 with sham CPAP in the early period, and 4.70 versus 3.41 in the late period. Older age was associated with 1.4-times higher odds of exceeding 4 hours nightly for each 10-year increase; active CPAP randomization had odds ratios of 1.85 early and 2.84 late for use above 4 hours. The adherence meta-analysis of randomized studies provides the trial-level context; these study-period figures are not routine-care estimates.
Apnea Reduction and CPAP Alternatives
The apnea-hypopnea index measures events per hour, so it captures a different outcome from sleepiness or nightly device use. Comparisons also depend on the alternative and the review’s publication window.
| Comparison | Result | Population and period |
|---|---|---|
| CPAP vs conservative management | AHI reduction of 25.4 events/hour | 77 RCTs, literature through August 2013 |
| MAD vs conservative management | AHI reduction of 9.3 events/hour | Same review and population |
| CPAP vs MAD | CPAP AHI 7.0 events/hour lower | Direct-comparison RCTs |
| APAP vs fixed CPAP | Difference of -0.20 AHI events/hour | 9 trials, 282 adults, through 2003 |
The 77-RCT review covered adults with obstructive sleep apnea-hypopnea and estimated a 7.0-event-per-hour CPAP advantage over mandibular advancement devices in direct comparisons. ESS differed by 0.67 points, not statistically significant, with a reported p value of 0.093. CPAP and mandibular advancement devices meta-analysis cautions that mandibular devices are an alternative comparator, not another CPAP group.
A later 14-RCT review through October 2019 included 249 CPAP and 247 MAD participants, or 496 adults. CPAP reduced AHI by 7.08 events per hour more than MAD and reduced stage 1 and 2 sleep percentage by 3.728 percentage points; there was no significant post-treatment ESS difference. CPAP versus mandibular advancement device notes that no significant difference does not establish identical effects.
For APAP, the older nine-trial meta-analysis of 282 adults found a post-treatment AHI difference of -0.20 events per hour, with a 95% confidence interval from -0.74 to 0.35. The ESS difference was -0.56 points, with a 95% confidence interval from -1.4 to 0.3, so both intervals crossed zero. Auto-titrating versus standard CPAP is an older small meta-analysis.
Blood Pressure and Cardiovascular CPAP Outcomes
A 12-week randomized trial enrolled adults with cardiovascular disease or multiple risk factors and obstructive sleep apnea. Of 318 participants, 281, or 88%, had ambulatory blood-pressure data at baseline and follow-up.
| 12-week comparison | Change in 24-hour mean arterial pressure |
|---|---|
| CPAP vs control | -2.4 mmHg |
| CPAP vs supplemental oxygen | -2.8 mmHg |
| Supplemental oxygen vs control | No significant difference |
The confidence intervals were -4.7 to -0.1 mmHg for CPAP versus control and -5.1 to -0.5 mmHg for CPAP versus supplemental oxygen. CPAP versus Oxygen in Obstructive Sleep Apnea studied a selected cardiovascular-risk population, so the result is not a general-population estimate.
An individual-participant meta-analysis combined SAVE, ISAACC and RICCADSA: 4,186 adults with cardiovascular disease and obstructive sleep apnea, followed for a mean 3.25 years. The group was 82.1% male, with mean age 61.2 years, BMI 28.9 kg/m² and baseline AHI 31.2 events per hour; 71% had hypertension.
CPAP versus usual care had a hazard ratio of 1.01 for a first major adverse cardiac or cerebrovascular event, with a 95% confidence interval of 0.87–1.17. Good adherence of at least 4 hours daily was associated with a hazard ratio of 0.69 for recurrent events in an on-treatment marginal structural analysis. Adherence to CPAP Treatment and Recurrent Cardiovascular Events warns that this association may reflect healthy-adherer effects and is not proof that CPAP prevents events for every patient.
CPAP Acceptance and Adherence Intervention Statistics
Support strategies can change observed use, but intervention results remain trial-specific. Thresholds and follow-up periods should be read alongside each percentage.
In a 379-person randomized trial of newly diagnosed SAHS patients in France, 65% receiving standard support used CPAP more than 3 hours nightly for four months, compared with 75% receiving five telephone coaching sessions. Phone coaching and CPAP adherence reports the trial-specific threshold and population.
Among 204 previously noncompliant patients, 49, or 24%, became compliant after mask optimization, humidification, nasal therapy and education, where compliance meant average nightly use of at least 4 hours. Among the persistently noncompliant subgroup continuing to phase 2, 15 of 53 CPAP patients, or 28%, achieved compliance after retitration over an additional 90 days, compared with 25 of 51, or 49%, assigned flexible bilevel. Interventions for previously non-compliant patients did not include an untreated control.
Motivational interviewing also produced a measurable difference in a randomized Australian trial. At three months, use averaged 4.63 hours nightly versus 3.16 with standard care among 100 adults with newly diagnosed obstructive sleep apnea; 50 of 53 randomized participants in each group met the primary analysis criteria, or 94%. Motivational interviewing and CPAP adherence reports the retention statistic separately from treatment effectiveness.
A 206-person social-cognitive trial reported CPAP uptake of 82% with standard intervention and 88% with social cognitive therapy. Adherence was 63–66% at one week and 55% versus 47% at six months across the two groups; the between-group differences were not statistically significant. Group social cognitive therapy used at least 4 hours nightly for its adherence definition.
Finally, a daytime 30- to 60-minute acclimation trial in 246 adults with moderate or severe obstructive sleep apnea produced 5.7 ± 1.0 hours nightly at one month versus 3.9 ± 1.1 with usual care. Daytime CPAP acclimation trial was a single randomized study in which acclimation occurred before the titration night.
CPAP Device-Market and Connected-Care Figures
Company revenue is not the same as global CPAP adoption or unit volume. ResMed’s device segment includes cloud-connected CPAP/APAP, bilevel, ASV and HFT devices, while residential-care software is a separate segment.
| ResMed measure | Fiscal 2023 | Fiscal 2024 | Fiscal 2025 |
|---|---|---|---|
| Devices as share of net revenue | 54% | 52% | 52% |
| Residential-care software as share of net revenue | 12% | 12% | 12% |
| Device revenue | — | $2,444.0 million | $2,665.2 million |
ResMed reported device-sales growth of 9% in the United States, Canada and Latin America and 10% in combined Europe, Asia and other markets in fiscal 2025. Device revenue increased by $221.2 million, or 9%, from fiscal 2024 to fiscal 2025. ResMed 2025 Form 10-K covers fiscal years ended June 30 and reports company segments rather than a standalone CPAP market.
The filing’s 52% device share should therefore be read as a broad company-revenue measure, not as a global CPAP prevalence statistic. Likewise, the 12% residential-care software share does not establish connected-CPAP adoption, and the reported regional growth rates are sales growth rather than unit growth.